Mycenax Biotech (4726)

TPEX

Currency in TWD

38.30

+0.50(+1.32%)

Closed·22/08

Fair Value

Unlock Value

Day's Range

37.50

38.50

52 wk Range

27.40

54.30

4726 Financial Summary

A brief financial summary of Mycenax Biotech as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Key Ratios

P/E Ratio-14.75

Price/Book4.18

Debt / Equity55.72%

Return on Equity-24.84%

Dividend Yield0.00%

EBITDA-206.91M

Fair ValueUnlock

Fair Value UpsideUnlock

Statements Highlights

Period Ending:

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

2024

31/12

Income Statement

Total Revenues

aa.aa

665.34

774.27

732.28

652.62

683.92

Gross Profit

aa.aa

186.53

137.61

-113.67

-375.19

-241.36

Operating Income

aa.aa

35.4

-85.33

-445

-602.1

-461.54

Net Income

aa.aa

30.95

-89.86

-453.63

-682.85

-467.13

Balance Sheet

Total Assets

aa.aa

1,752.55

3,139.01

4,453

3,770.4

3,368.38

Total Current Liabilities

aa.aa

424.78

540.07

634.73

753.42

661.5

Total Equity

aa.aa

1,211.67

1,906.67

3,105.58

2,447.19

2,023.48

Cash Flow

Levered Free Cash Flow

aa.aa

-82.2

-1,167.82

-662.5

-6.76

-489.76

Cash from Operations

aa.aa

174.17

-146.23

-150.19

-131.18

-191.68

Cash from Investing

aa.aa

-168.58

-1,031.48

-745.24

-443.15

-174.93

Cash from Financing

aa.aa

91.88

1,173.5

1,931.87

-229.73

116.58

Net Change in Cash

aa.aa

97.47

-4.21

1,036.44

-804.1

-249.7

* In Millions of TWD (except for per share items)

Earnings

Latest Release

Aug 07, 2025

EPS / Forecast

-0.66 / -0.14

Revenue / Forecast

202.56M / 293.00M

EPS Revisions

Unlock

Last 90 days

FAQ

What were Mycenax Biotech's earnings for the latest quarter?

The Mycenax Biotech EPS (TTM) is -2.41. Mycenax Biotech reported sales of 202.56, net income of -137.16, and EPS of -0.66 for the latest quarter.

What was Mycenax Biotech's net income for the latest quarter?

Mycenax Biotech's net income for the latest quarter was -137.16.

How did Mycenax Biotech's performance compare year-over-year in the latest quarter?

The company's revenue moved from 121.72 in the previous quarter to 202.56 in the latest quarter, and net income moved from -129.14 to -137.16 compared to the previous quarter.

What is Mycenax Biotech's net profit margin on a TTM basis?

Mycenax Biotech's trailing twelve months (TTM) net profit margin is -68.30%.

How does Mycenax Biotech's debt to equity ratio compare to industry standards?

Mycenax Biotech's total debt-to-equity ratio is 55.72%.

What is Mycenax Biotech's return on investment on a TTM basis?

Mycenax Biotech's trailing twelve months (TTM) return on investment (ROI) is -24.84%.

Did Mycenax Biotech gain or lose cash last quarter?

In the latest quarter, Mycenax Biotech's net change in cash was -53.48 million.

What were Mycenax Biotech's total assets and liabilities in the latest quarter?

As of the latest quarter, Mycenax Biotech reported total assets of 3,214.92 million and total liabilities of 841.51 million.

How has Mycenax Biotech's total revenue grown this year?

Mycenax Biotech's total revenue was 121.72 in the previous quarter and 202.56 in the latest quarter.

What is Mycenax Biotech's gross margin on a TTM basis?

Mycenax Biotech's trailing twelve months (TTM) gross margin is -30.97%.

What was Mycenax Biotech's revenue per share for the latest quarter?

Mycenax Biotech's revenue per share for the latest quarter was 3.34.

NSE 30

5,152.99

+13.06

+0.25%

NSE All Share

141,439.75

+435.61

+0.31%

US 30

45,448.70

-183.0

-0.40%

US 500

6,463.50

-3.4

-0.05%

FTSE 100

9,321.40

+12.20

+0.13%

DAX

24,265.30

-105.44

-0.43%

South Africa Top 40

95,329.31

+262.45

+0.28%

Market Movers

Name	Last	Chg. %	Vol.
Fcmb	10.900	-0.91%	87.12M
Guaranty Trust Holding	96.05	+2.18%	25.00M
Access Holdings	27.45	+1.67%	15.69M
UBA	47.95	0.00%	14.23M
Zenith Bank	70.00	0.00%	10.18M
Aradel Holdings	510.00	-1.73%	2.66M
Julius Berger	146.10	+9.93%	2.15M

Name	Last	Chg. %	Vol.
Julius Berger	146.10	+9.93%	2.15M
Cutix	3.900	+9.86%	2.13M
Regal Insurance	1.47	+9.70%	15.85M
Veritas Kapital	2.17	+9.60%	58.37M
McNichols	3.50	+9.37%	677.72K
Nem	28.950	+8.83%	529.28K
Universal Insurance PLC	1.32	+8.20%	33.56M

Name	Last	Chg. %	Vol.
University Pre	5.540	-12.06%	681.46K
Cadbury Nig	57.85	-9.61%	660.41K
Abbey Mortgage Bank	6.55	-8.39%	254.88K
Daarcomm	1.12	-7.44%	3.04M
Austin Laz	2.71	-6.55%	2.59M
Mecure Industries	19.50	-6.02%	421.01K
Tantalizers	2.50	-5.66%	4.86M

Trending Stocks

Name	Last	Chg. %	Vol.
Mutual Benefits Assurance	4.45	+1.14%	18.05M
MTN Nigeria	435.00	0.00%	707.31K
Aiico	4.47	+6.94%	26.20M
Dangote Cement	520.00	0.00%	111.45K
Betaglas	449.35	0.00%	142.48K

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaa Aa Aaaaaa Aa	5,379.30	+46.90%	7,902.19
Aaaaaaaa	520.00	+35.88%	706.58
Aaaa Aa	151.80	+31.85%	200.15
Aaaaaa Aa	1,890.00	+30.65%	2,469.28
A Aaaaaaaaaaaaa	70.20	+18.13%	82.93
Aaaaaaaaaaa	640.00	+17.25%	750.40

Name	Last	Upside	Fair Value
Aaaa Aa Aaaaaa Aa	5,379.30	+46.90%	7,902.19
Aaaaaaaa	520.00	+35.88%	706.58
Aaaa Aa	151.80	+31.85%	200.15
Aaaaaa Aa	1,890.00	+30.65%	2,469.28
A Aaaaaaaaaaaaa	70.20	+18.13%	82.93
Aaaaaaaaaaa	640.00	+17.25%	750.40

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

Mycenax Biotech (4726)

4726 Financial Summary

Key Ratios

Statements Highlights

Earnings

FAQ

What were Mycenax Biotech's earnings for the latest quarter?

What was Mycenax Biotech's net income for the latest quarter?

How did Mycenax Biotech's performance compare year-over-year in the latest quarter?

What is Mycenax Biotech's net profit margin on a TTM basis?

How does Mycenax Biotech's debt to equity ratio compare to industry standards?

What is Mycenax Biotech's return on investment on a TTM basis?

Did Mycenax Biotech gain or lose cash last quarter?

What were Mycenax Biotech's total assets and liabilities in the latest quarter?

How has Mycenax Biotech's total revenue grown this year?

What is Mycenax Biotech's gross margin on a TTM basis?

What was Mycenax Biotech's revenue per share for the latest quarter?

Trending Stocks